Analysis of Somatostatin-Receptor 2A (SSTR2A) Immunohistochemistry, RT-qPCR and In-Vivo- PET/CT Data in Patients with Pancreatic Neuroendocrine Neoplasm Abstract #803

Introduction: Ga-68 somatostatin receptor (SSTR) PET/CT is one of the most sensitive imaging methods for pancreatic neuroendocrine tumors.
Aim(s): We analyzed if the receptor density predicted by the semi-quantitative parameters generated from the static PET/CT (standard uptake values – SUVmax / SUVmean) correlate with ex-vivo SSTR2A immunohistochemistry (IHC) and RT-qPCR gene expression data.
Materials and methods: Twenty-three pancreatic neuroendocrine tumor specimens (14 primary tumors, nine metastases) of 15 patients were evaluated. PET/CT was performed preoperatively in all patients. SSTR2A and Ki-67 expression was quantified immunohistochemically using the Immunoreactive Score (IRS), according to Remmele and Stegner as well as by means of RT-qPCR.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Daniel Kaemmerer

To read results and conclusion, please login ...

Further abstracts you may be interested in

#13 Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic carcinoma
Introduction: Pancreatic endocrine tumors (pNETs) are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis, many of them are already advanced and difficult to treat.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#195 UMB-4 as New Monoclonal Somatostatin Receptor Antibody: Correlation of Immunostaining with Molecular Imaging using Somatostatin Receptor PET/CT
Introduction: Somatostatin receptors (SSTR) are known for an overexpression in neuroendocrine tumors (NET).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
Authors: Kaemmerer D, Peter L, Lupp A, Schulz S, ...
#563 Role of Ga-68 Somatostatin Receptor PET/CT in the Assessment of Response to Radiofrequency Ablation in Hepatic Metastases of Neuroendocrine Tumors
Introduction: Patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) present frequently with hepatic metastases. Radiofrequency ablation (RFA) is an important local ablative treatment for hepatic metastases.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Richard P Baum
#657 Correlation of Monoclonal and Polyclonal Somatostatin Receptor (SSTR) 5 Antibodies in Pancreatic Neuroendocrine Tumors
Introduction: For a few years now, highly specific monoclonal antibodies have been available to characterize neuroendocrine tumors for somatostatin-receptor (SSTR) expression.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr. Daniel Kaemmerer
Authors: Kaemmerer D, Lupp A, Peter L, Fischer E, ...